Mar 13, 2023 / 06:40PM GMT
Hartaj Singh - Oppenheimer & Co. Inc. - Analyst
Great. Thank you so very much. Again, thanks to the operators for making this so easy. People, I think, have little idea of how much technical stuff -- hurdles need to be overcome.
We have with us Megan Baldwin and Tim from Opthea. I've gotten to know Tim just recently; Megan for a very, very, very long period of time. And Megan has been doing stellar work in getting Opthea in two Phase 3 trials in wet AMD, with some really great data in Phase 2, both in wet AMD and DME. And we'll talk about that today.
So both of you, welcome. I really appreciate having you here.
Tim Morris - Opthea Limited - CFO
Thanks, Hartaj.
Megan Baldwin - Opthea Limited - CEO & Managing Director
Thanks, Hartaj.
Hartaj Singh - Oppenheimer & Co. Inc. - Analyst
And maybe what we can do is -- Megan, if you want to just give us about a five-minute overview of where the company is now, and then we can go from there.
Opthea Ltd at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers